Culture-medium development/Cell processing development

Culture-medium development service for cell and gene therapy products

With an increase in the use of cell and gene therapy, manufacturing cost is an unavoidable issue. As the manufacturing scale rises, the cost of the medium essential for cell culture expands, and in particular the proportion of expensive medium components such as cytokines may account for the majority of the entire manufacturing cost.   We solve the challenges faced by companies developing regenerative medicine and other products, such as medium cost, cell yield, and bio-derived raw materials, by utilizing our own small molecules database and patent-pending medium component search technology.   Up until now, we have successfully replaced all of the proteins contained in culture medium with small molecules in the process of cardiomyocyte differentiation from iPS cells. Based on this technology and experience, we will support companies developing cell products. As a search method, the medium that you are currently using may be selected, or development may be conducted based on our own basal medium.   - Protein-free or less culture-medium development system - Experiences on cardiomyocytes, blood related cells, cancer cells and others  

Our technology: Protein-free culture on cardiomyocytes

Successfully reduce costs of culture-medium to 1/100 - Patented cardiomyocyte differentiation method - Only small molecules/amino acids (protein/peptide-free) - Featured in Cell Reports Best of 2012 - Spun out from Kyoto University in 2016

Our technology: Cell processing development

For companies developing cell products, the serious problems comparable to the challenges of “medium” are concerns about cell manufacturing, such as a shortage of cells for treatment, difficult market expansion due to high costs even if the product is finally launched, and limited capital investment in cell processing facilities.   We solve the cost issues faced by companies developing cell products – i.e., cell yield, personnel expenses, cost of equipment, with our own scale-up technology that keeps mechanized cell production in sight, and through alliance and collaboration with equipment manufacturers.   Through collaboration with equipment manufacturers who own and develop machinery and equipment for cell culture, as well as manufacturers of culture substrates and chemical products, we have developed manufacturing processes which may be difficult for companies developing cell products to do alone. One of our representative achievements, in collaboration with Hitachi, Ltd, is an automated cultivation of iPS cell-derived cardiomyocytes in a closed system.   Based on these technologies and experiences, our engineers will support you with manual procedures suitable for your cells and the development of manufacturing processes by using culture substrates, machines, and equipment.